Samuel Wagner

TL;DR: The global HCC BRIDGE study was a multiregional, large‐scale, longitudinal cohort study undertaken to improve understanding of real‐life management of patients with HCC, from diagnosis to death.

TL;DR: This analysis supports using cure modeling in health economic evaluation in advanced melanoma by showing that using cure models may reduce bias in OS estimates and provide more accurate estimates of health economic measures, including QALYs and ICERs.

TL;DR: Ipilimumab with/without gp100 vaccine does not have a significant negative HRQL impact during the treatment induction phase relative to gp100 alone in stage III or IV melanoma patients.

TL;DR: Parametric assessment of mean survival gain in clinical trials may indicate potential benefits to patients that observed medians may greatly underestimate, and is compared with median survival in a case study of a recent trial in metastatic melanoma.

TL;DR: Evidence is provided for a positive association between treatment effects on PFS and OS and studies involving patient level data are necessary to confirm whether PFS is a valid surrogate for OS in MM.